OncoDaily Pulse

Aug 26, 2025, 13:16

Elizabeth Liow: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register via the link.

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Elizabeth Liow

Dr. Elizabeth Liow is a Medical Oncologist and Head of the Australian KRAB Registry, as well as an Adjunct Lecturer at Monash University. She is widely recognized for her clinical and academic dedication to advancing renal oncology in Australia.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Liow will present on “The Current State of Renal Oncology in Australia”. Her presentation will cover:

Current trends, challenges, and significant advancements in managing renal cancer within the Australian healthcare setting.
Valuable insights derived from the Australian KRAB Registry, highlighting its critical role in informing patient care and research strategies.
The adoption of novel therapies and diagnostic tools integrated into Australia’s clinical practice tailored to renal oncology.
Future directions aimed at improving clinical outcomes and fostering collaborative efforts in renal cancer research and treatment across Australia.

Through her clinical expertise and leadership of the KRAB Registry, Dr. Liow emphasizes a comprehensive and Australia-focused understanding of renal oncology, striving to enhance patient care and accelerate research innovation nationally.